Tonix Pharmaceuticals Holding Corp (OQ:TNXP)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 26 Main Street, Suite 101
CHATHAM NJ 07928
Tel: N/A
Website: https://www.tonixpharma.com
IR: See website
<
Key People
Seth Lederman
Chairman of the Board, President, Chief Executive Officer
Bradley Saenger
Chief Financial Officer, Treasurer
Jessica Edgar Morris
Chief Operating Officer
Zeil Rosenberg
Executive Vice President - Medical
Gregory M. Sullivan
Secretary, Chief Medical Officer
 
Business Overview
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Financial Overview
For the fiscal year ended 31 December 2023, Tonix Pharmaceuticals Holding Corp revenues increased from $0K to $7.8M. Net loss applicable to common stockholders increased less than 1% to $116.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Stock-based Compensation in SGA decrease of 19% to $6.4M (expense).
Employees: 103 as of Apr 1, 2024
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $7.77M as of Dec 31, 2023
EBITDA (TTM): -$114.09M as of Dec 31, 2023
Net annual income (TTM): -$116.66M as of Dec 31, 2023
Free cash flow (TTM): -$109.90M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 84,490,862 as of Apr 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.